MedTrace Logo

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

NCT04346199 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 177

Last updated 2021-09-17

Study results available
· View outcomes & findings →

Summary

CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

Conditions

Interventions

DRUG

Acalabrutinib

Acalabrutinib- administered orally

Sponsors & Collaborators

  • Acerta Pharma BV

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-12
Primary Completion
2020-11-17
Completion
2020-11-17
FDA Drug
Yes

Countries

  • Argentina
  • Brazil
  • Chile
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Mexico
  • Peru
  • Poland
  • Russia
  • South Africa
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04346199 on ClinicalTrials.gov